2025-10-19 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc. (HIMS) based on the provided information, presented in a structured report format.

## Hims & Hers Health Inc. (HIMS) Analysis

Hims & Hers Health Inc. is a telehealth company that offers personalized health and wellness solutions directly to consumers.

### 1. Performance Relative to S&P 500 (VOO)

*   **HIMS Cumulative Return:** 225.12%
*   **VOO Cumulative Return:** 71.01%
*   **Absolute Divergence:** 183.8%
*   **Relative Divergence:** 66.2% (This means the current divergence is at the 66.2 percentile of its historical range).

**Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) over the analyzed period. However, the relative divergence suggests that while the outperformance is substantial, it's not at its absolute highest historical level, indicating some recent cooling off from peak outperformance.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2019-2021  | -42.0%  | 74.4% | -81.0% | 0.0  | 1.5    |
| 2020-2022  | -19.0%  | 78.6% | -18.0% | -0.0 | 1.4    |
| 2021-2023  | -65.0%  | 78.6% | -67.0% | -0.1 | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0%  | -0.0 | 5.5    |
| 2023-2025  | 230.0% | 82.4% | 168.0% | 0.1  | 11.2   |

**Analysis:**

*   **CAGR Trend:** The CAGR has dramatically improved in recent periods, indicating strong growth momentum.  The negative CAGR in earlier periods is concerning but appears to be turning around.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant volatility and risk.
*   **Alpha:** The Alpha values show a recent surge in outperformance compared to the market. The earlier negative Alpha suggests underperformance in earlier periods.
*   **Beta:** The Beta values are around 0, indicating that the stock is not strongly correlated with the market.  The small beta may mean that the stock's movements are more influenced by company-specific factors than broad market trends.
*   **Cap:** The market capitalization has increased significantly, reflecting the company's growth.

### 2. Recent Price Action

*   **Current Price:** $49.78
*   **Previous Close:** $59.15
*   **Change:** -15.84%
*   **5-Day Moving Average:** $56.09
*   **20-Day Moving Average:** $55.95
*   **60-Day Moving Average:** $52.47

**Analysis:** The stock price has experienced a significant drop (-15.84%) compared to the previous close. The current price is below both the 5-day and 20-day moving averages, suggesting a short-term downward trend. The price is still above 60-day moving average, so it can not say that the downward trend continues.

### 3. Market Risk Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment)
*   **RSI:** 41.11
*   **PPO:** -0.82
*   **Hybrid Signal:** Sell 80% of holdings
*   **20-Day Relative Divergence Change:** -5.9 (Negative - indicating recent underperformance)
*   **Expected Return:** 3.0% (Annualized excess return over S&P 500 with long-term, consistent investment)

**Analysis:**

*   **MRI:** The MRI of 0.5 suggests a "Low Investment" recommendation.
*   **RSI:** The RSI of 41.11 is near the oversold threshold (30), potentially indicating a possible rebound, but also showing strong selling pressure.
*   **PPO:** The negative PPO (-0.82) also signals a short-term downward trend.
*   **Hybrid Signal:** The "Sell 80%" signal reinforces the short-term bearish outlook.
*   **Relative Divergence Change:** The negative change in relative divergence supports the recent underperformance.
*   **Expected Return:** The 3.0% expected return suggests moderate long-term potential but doesn't account for short-term volatility.
*   **Price Change Impact:** The significant price drop compared to the previous close strongly indicates a negative catalyst affecting the stock.

### 4. Recent News & Significant Events

*   **Menopause Launch:** Potential positive catalyst, shaping valuation and growth expectations.
*   **CEO Sells Stake:** Significant negative signal, raising concerns about insider confidence.
*   **Analyst Calls & Comparisons:** Mixed opinions, some suggesting alternative value stocks (OMCL).
*   **Reasons for Price Decline:** Articles highlight factors contributing to the recent drop.

**Analysis:** Recent news is mixed. While the new product launch (menopause solutions) could be a positive long-term driver, the CEO's sale of a large stake is a significant red flag and likely contributing to the recent price decline. Analyst opinions seem divided, with some suggesting better value opportunities elsewhere.

### 4-2. Analyst Opinions

*   **Consensus:** Hold (Mean = 2.92)
*   **Target Price:** $47.42 (average)
*   **Recent Rating Changes:** None Specified

**Analysis:** The analyst consensus is "Hold," suggesting a neutral outlook. The average target price ($47.42) is below the current price ($49.78), indicating potential downside risk according to analysts.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-04 | 0.19 | 0.54 B$    |
| 2025-05-05 | 0.22 | 0.59 B$    |
| 2024-11-04 | 0.35 | 0.40 B$    |
| 2024-08-05 | 0.06 | 0.32 B$    |
| 2025-08-04 | 0.06 | 0.32 B$    |

**Analysis:**

*   **Trend:**  Recent EPS and revenue figures show a generally increasing trend.
*   **Inconsistency:** There is a duplicate date (2025-08-04) with significantly different values, suggesting a possible data error. Assuming the 2025-08-04 with EPS 0.19 and Revenue 0.54B is correct, the trend shows improvement in both EPS and Revenue.

### 6. Financial Information

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.54B  | 76.39%        |
| 2025-03-31 | $0.59B  | 73.50%        |
| 2024-12-31 | $0.48B  | 76.81%        |
| 2024-09-30 | $0.40B  | 79.16%        |
| 2024-06-30 | $0.32B  | 81.30%        |

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-06-30 | $0.56B  | 7.55%    |
| 2025-03-31 | $0.55B  | 9.01%    |
| 2024-12-31 | $0.48B  | 5.46%    |
| 2024-09-30 | $0.44B  | 17.18%   |
| 2024-06-30 | $0.36B  | 3.67%    |

**Analysis:**

*   **Revenue:** Revenue has been consistently increasing over the past few quarters, indicating strong top-line growth.
*   **Profit Margin:** Profit margins are high and relatively stable, suggesting good operational efficiency.  There's a slight dip in the most recent quarter, but overall, the margins are healthy.
*   **Equity:** Equity has also been increasing, reflecting the company's growing asset base.
*   **ROE:** Return on Equity (ROE) is volatile. The high ROE in 2024-09-30 suggests efficient use of equity at that time, but the recent decline might warrant further investigation.

### 7. Overall Summary and Recommendation

Hims & Hers Health Inc. (HIMS) has shown significant outperformance compared to the S&P 500, driven by strong revenue growth and high profit margins. However, recent events, including a significant price drop, CEO's share sale, and mixed analyst opinions, raise concerns about the short-term outlook.

**Key Considerations:**

*   **Growth Potential:** The company's expansion into new markets (e.g., menopause solutions) presents potential growth opportunities.
*   **Volatility:** The stock exhibits high volatility, as indicated by the high MDD values.
*   **Insider Activity:** The CEO's share sale is a significant negative signal.
*   **Technical Indicators:** Technical indicators suggest a short-term downward trend.

**Recommendation:**

Given the mixed signals, a **neutral to cautious** stance is warranted. The company's long-term growth potential is promising, but the recent negative events and technical indicators suggest potential short-term downside risk. Investors should closely monitor the company's performance, insider activity, and analyst ratings before making any investment decisions. It might be wise to wait for stabilization and more positive signals before considering an entry point. The hybrid signal is 80% sell.
